Profile data is unavailable for this security.
About the company
Shanghai Fosun Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates in five segments. Pharmaceutical segment is mainly engaged in the manufacturing of innovative drugs, mature pharmaceutical products and vaccines. Medical Devices and Medical Diagnostics segment is mainly engaged in the manufacturing and sales of medical cosmetic devices such as molecular diagnosis, immunodiagnosis, and microbial diagnosis. Medical Health Services segment is mainly engaged in the operation of an online and offline integrated medical service platform. Pharmaceutical Distribution and Retail segment is mainly engaged in the wholesale and retail of pharmaceutical products. Others segment is engaged in other pharmaceutical-related businesses. The Company's products are mainly used in the treatment of tumors, immunity, central nervous system and other fields.
- Revenue in CNY (TTM)41.61bn
- Net income in CNY2.11bn
- Incorporated1995
- Employees40.37k
- LocationShanghai Fosun Pharmaceutical Group Co LtdBuilding A, No. 1289 Yishan RoadSHANGHAI 200233ChinaCHN
- Phone+86 2 133987870
- Fax+86 2 133987871
- Websitehttps://www.fosunpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical Co Ltd | 5.21bn | 255.55m | 33.27bn | 4.41k | 129.59 | 4.73 | -- | 6.38 | 0.0185 | 0.0185 | 0.3766 | 0.5079 | 0.3626 | 1.45 | 2.55 | 1,182,457.00 | 1.80 | -17.60 | 2.77 | -32.24 | 20.63 | -72.78 | 4.95 | -101.19 | 0.8398 | -- | 0.0346 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Humanwell Healthcare Group Co Ltd | 25.56bn | 1.96bn | 38.85bn | 17.68k | 19.64 | 2.17 | -- | 1.52 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Beijing Tiantan Biological Products Corp | 5.23bn | 1.27bn | 43.56bn | 4.86k | 34.19 | 4.09 | -- | 8.33 | 0.6444 | 0.6444 | 2.65 | 5.38 | 0.3471 | 0.8137 | 198.92 | 1,076,946.00 | 11.47 | 11.71 | 16.75 | 16.50 | 54.23 | 49.39 | 33.05 | 27.71 | 3.31 | -- | 0.0046 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 38.97 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 76.39bn | 3.42bn | 44.37bn | 28.05k | 13.74 | 1.30 | -- | 0.5808 | 2.11 | 2.11 | 46.99 | 22.28 | 0.9946 | 6.07 | 4.60 | 2,723,576.00 | 4.71 | 5.90 | 8.93 | 12.40 | 16.55 | 18.70 | 4.74 | 5.56 | 1.15 | -- | 0.317 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
| Beijing Tongrentang Co Ltd | 17.96bn | 1.63bn | 56.09bn | 16.78k | 34.45 | 4.32 | -- | 3.12 | 1.19 | 1.19 | 13.09 | 9.46 | 0.5912 | 1.08 | 11.14 | 1,070,467.00 | 7.88 | 8.20 | 15.63 | 16.17 | 44.48 | 46.59 | 13.33 | 13.33 | 1.58 | -- | 0.1765 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
| Shanghai Fosun Pharmaceutical (Group) | 41.61bn | 2.11bn | 65.23bn | 40.37k | 34.62 | 1.54 | -- | 1.57 | 0.7883 | 0.7883 | 15.54 | 17.71 | 0.3682 | 2.86 | 5.10 | 1,030,748.00 | 2.44 | 4.31 | 4.18 | 7.01 | 47.10 | 50.71 | 6.63 | 10.65 | 0.7221 | -- | 0.3755 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Sichuan Biokin Pharmaceutical Co Ltd | 5.85bn | 3.80bn | 80.56bn | 2.09k | 21.20 | 18.99 | -- | 13.78 | 9.48 | 9.48 | 14.58 | 10.58 | 1.40 | 1.81 | 64.16 | 2,802,843.00 | 90.79 | -- | 138.20 | -- | 95.33 | -- | 64.99 | -- | 2.89 | -- | 0.2807 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 2.49bn | -294.04m | 93.53bn | 3.84k | -- | 7.53 | -- | 37.56 | -0.2393 | -0.2393 | 1.97 | 9.82 | 0.1596 | 0.7843 | 0.7758 | 647,931.10 | -1.89 | 24.08 | -2.26 | 31.80 | 69.01 | 85.18 | -11.84 | 34.95 | 4.18 | -- | 0.0238 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 25.55m | 1.21% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2024 | 15.19m | 0.72% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 10.51m | 0.50% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 9.42m | 0.45% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2024 | 8.36m | 0.40% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 8.09m | 0.38% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 7.75m | 0.37% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 7.65m | 0.36% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 5.50m | 0.26% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 2.71m | 0.13% |
